Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Feb;39(2):476–483. doi: 10.1128/aac.39.2.476

CP-115,953 stimulates cytokine production by lymphocytes.

K Riesbeck 1, A Forsgren 1
PMCID: PMC162563  PMID: 7726518

Abstract

The cytotoxic quinolone CP-115,953 specifically exerts its inhibitory effect upon eukaryotic topoisomerase II. CP-115,953 stimulates DNA cleavage mediated by topoisomerase II with a potency approximately 600 times greater than that of ciprofloxacin, a quinolone antibacterial agent that currently is in clinical use. Because ciprofloxacin has been reported to strongly enhance interleukin-2 production, we considered it important to study the effect of CP-115,953 on interleukin-2 and gamma interferon (IFN-gamma) mRNA and protein expression in mitogen-stimulated human peripheral blood lymphocytes. For comparison, novobiocin and the antineoplastic drug etoposide were also included in the study. CP-115,953 (25 microM) enhanced interleukin-2 mRNA levels up to 8-fold and IFN-gamma mRNA concentrations up to 6.5-fold. In contrast, ciprofloxacin (282 microM) induced mRNAs for interleukin-2 and IFN-gamma up to 20-fold and 7.8-fold, respectively. However, CP-115,953 showed more prolonged kinetics of IFN-gamma mRNA production than ciprofloxacin. At high concentrations (> or = 141 microM), ciprofloxacin was a greater inducer of interleukin-2 production and exhibited a higher level of stimulatory action than CP-115,953 on IFN-gamma synthesis. At low concentrations, however, CP-115,953 (< or = 25 microM) was more potent than ciprofloxacin in inducing interleukin-2 and IFN-gamma synthesis. Etoposide or novobiocin did not influence cytokine mRNA expression. Thus, among the topoisomerase II inhibitors tested, fluoroquinolones are unique in stimulating cytokine synthesis in lymphocyte cultures.

Full Text

The Full Text of this article is available as a PDF (364.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abdul Hamied T. A., Parker D., Turk J. L. Effects of adriamycin, 4-hydroperoxycyclophosphamide and ASTA Z 7557 (INN mafosfamide) on the release of IL-2 and IL-1 in vitro. Int J Immunopharmacol. 1987;9(3):355–361. doi: 10.1016/0192-0561(87)90061-0. [DOI] [PubMed] [Google Scholar]
  2. Ahmed K., Turk J. L. Effect of anticancer agents neothramycin, aclacinomycin, FK-565 and FK-156 on the release of interleukin-2 and interleukin-1 in vitro. Cancer Immunol Immunother. 1989;28(2):87–92. doi: 10.1007/BF00199107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Asahina Y., Ishizaki T., Suzue S. Recent advances in structure activity relationships in new quinolones. Prog Drug Res. 1992;38:57–106. [PubMed] [Google Scholar]
  4. Barrett J. F., Gootz T. D., McGuirk P. R., Farrell C. A., Sokolowski S. A. Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents. Antimicrob Agents Chemother. 1989 Oct;33(10):1697–1703. doi: 10.1128/aac.33.10.1697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Barrett J. F., Sutcliffe J. A., Gootz T. D. In vitro assays used to measure the activity of topoisomerases. Antimicrob Agents Chemother. 1990 Jan;34(1):1–7. doi: 10.1128/aac.34.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bredberg A., Brant M., Riesbeck K., Azou Y., Forsgren A. 4-Quinolone antibiotics: positive genotoxic screening tests despite an apparent lack of mutation induction. Mutat Res. 1989 Mar;211(1):171–180. doi: 10.1016/0027-5107(89)90117-6. [DOI] [PubMed] [Google Scholar]
  7. Brou C., Kuhn A., Staub A., Chaudhary S., Grummt I., Davidson I., Tora L. Sequence-specific transactivators counteract topoisomerase II-mediated inhibition of in vitro transcription by RNA polymerases I and II. Nucleic Acids Res. 1993 Aug 25;21(17):4011–4018. doi: 10.1093/nar/21.17.4011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chae H. P., Jarvis L. J., Uckun F. M. Role of tyrosine phosphorylation in radiation-induced activation of c-jun protooncogene in human lymphohematopoietic precursor cells. Cancer Res. 1993 Feb 1;53(3):447–451. [PubMed] [Google Scholar]
  9. Chen G. L., Yang L., Rowe T. C., Halligan B. D., Tewey K. M., Liu L. F. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem. 1984 Nov 10;259(21):13560–13566. [PubMed] [Google Scholar]
  10. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  11. Corbett A. H., Guerry P., Pflieger P., Osheroff N. A pyrimido[1,6-a]benzimidazole that enhances DNA cleavage mediated by eukaryotic topoisomerase II: a novel class of topoisomerase II-targeted drugs with cytotoxic potential. Antimicrob Agents Chemother. 1993 Dec;37(12):2599–2605. doi: 10.1128/aac.37.12.2599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Corbett A. H., Hong D., Osheroff N. Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme. J Biol Chem. 1993 Jul 5;268(19):14394–14398. [PubMed] [Google Scholar]
  13. Devary Y., Gottlieb R. A., Smeal T., Karin M. The mammalian ultraviolet response is triggered by activation of Src tyrosine kinases. Cell. 1992 Dec 24;71(7):1081–1091. doi: 10.1016/s0092-8674(05)80058-3. [DOI] [PubMed] [Google Scholar]
  14. Elsea S. H., McGuirk P. R., Gootz T. D., Moynihan M., Osheroff N. Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential. Antimicrob Agents Chemother. 1993 Oct;37(10):2179–2186. doi: 10.1128/aac.37.10.2179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Elsea S. H., Osheroff N., Nitiss J. L. Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast. J Biol Chem. 1992 Jul 5;267(19):13150–13153. [PubMed] [Google Scholar]
  16. Fornace A. J., Jr, Alamo I., Jr, Hollander M. C. DNA damage-inducible transcripts in mammalian cells. Proc Natl Acad Sci U S A. 1988 Dec;85(23):8800–8804. doi: 10.1073/pnas.85.23.8800. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Forsgren A., Bredberg A., Pardee A. B., Schlossman S. F., Tedder T. F. Effects of ciprofloxacin on eucaryotic pyrimidine nucleotide biosynthesis and cell growth. Antimicrob Agents Chemother. 1987 May;31(5):774–779. doi: 10.1128/aac.31.5.774. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Freudenreich C. H., Kreuzer K. N. Mutational analysis of a type II topoisomerase cleavage site: distinct requirements for enzyme and inhibitors. EMBO J. 1993 May;12(5):2085–2097. doi: 10.1002/j.1460-2075.1993.tb05857.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Froelich-Ammon S. J., McGuirk P. R., Gootz T. D., Jefson M. R., Osheroff N. Novel 1-8-bridged chiral quinolones with activity against topoisomerase II: stereospecificity of the eukaryotic enzyme. Antimicrob Agents Chemother. 1993 Apr;37(4):646–651. doi: 10.1128/aac.37.4.646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Gellert M. DNA topoisomerases. Annu Rev Biochem. 1981;50:879–910. doi: 10.1146/annurev.bi.50.070181.004311. [DOI] [PubMed] [Google Scholar]
  21. Gootz T. D., Barrett J. F., Sutcliffe J. A. Inhibitory effects of quinolone antibacterial agents on eucaryotic topoisomerases and related test systems. Antimicrob Agents Chemother. 1990 Jan;34(1):8–12. doi: 10.1128/aac.34.1.8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Herrlich P., Ponta H., Rahmsdorf H. J. DNA damage-induced gene expression: signal transduction and relation to growth factor signaling. Rev Physiol Biochem Pharmacol. 1992;119:187–223. doi: 10.1007/3540551921_7. [DOI] [PubMed] [Google Scholar]
  23. Holbrook N. J., Fornace A. J., Jr Response to adversity: molecular control of gene activation following genotoxic stress. New Biol. 1991 Sep;3(9):825–833. [PubMed] [Google Scholar]
  24. Hollander M. C., Fornace A. J., Jr Induction of fos RNA by DNA-damaging agents. Cancer Res. 1989 Apr 1;49(7):1687–1692. [PubMed] [Google Scholar]
  25. Hooper D. C. Quinolone mode of action--new aspects. Drugs. 1993;45 (Suppl 3):8–14. doi: 10.2165/00003495-199300453-00004. [DOI] [PubMed] [Google Scholar]
  26. Hoshino K., Sato K., Akahane K., Yoshida A., Hayakawa I., Sato M., Une T., Osada Y. Significance of the methyl group on the oxazine ring of ofloxacin derivatives in the inhibition of bacterial and mammalian type II topoisomerases. Antimicrob Agents Chemother. 1991 Feb;35(2):309–312. doi: 10.1128/aac.35.2.309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Hussy P., Maass G., Tümmler B., Grosse F., Schomburg U. Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts. Antimicrob Agents Chemother. 1986 Jun;29(6):1073–1078. doi: 10.1128/aac.29.6.1073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Janssen Y. M., Van Houten B., Borm P. J., Mossman B. T. Cell and tissue responses to oxidative damage. Lab Invest. 1993 Sep;69(3):261–274. [PubMed] [Google Scholar]
  29. Kletter Y., Riklis I., Shalit I., Fabian I. Enhanced repopulation of murine hematopoietic organs in sublethally irradiated mice after treatment with ciprofloxacin. Blood. 1991 Oct 1;78(7):1685–1691. [PubMed] [Google Scholar]
  30. Kohlbrenner W. E., Wideburg N., Weigl D., Saldivar A., Chu D. T. Induction of calf thymus topoisomerase II-mediated DNA breakage by the antibacterial isothiazoloquinolones A-65281 and A-65282. Antimicrob Agents Chemother. 1992 Jan;36(1):81–86. doi: 10.1128/aac.36.1.81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Krämer M., Sachsenmaier C., Herrlich P., Rahmsdorf H. J. UV irradiation-induced interleukin-1 and basic fibroblast growth factor synthesis and release mediate part of the UV response. J Biol Chem. 1993 Mar 25;268(9):6734–6741. [PubMed] [Google Scholar]
  32. Luethy J. D., Holbrook N. J. Activation of the gadd153 promoter by genotoxic agents: a rapid and specific response to DNA damage. Cancer Res. 1992 Jan 1;52(1):5–10. [PubMed] [Google Scholar]
  33. Matsuo K., Kohno K., Sato S., Uchiumi T., Tanimura H., Yamada Y., Kuwano M. Enhanced expression of the DNA topoisomerase II gene in response to heat shock stress in human epidermoid cancer KB cells. Cancer Res. 1993 Mar 1;53(5):1085–1090. [PubMed] [Google Scholar]
  34. Micallef M., Hosokawa M., Shibata T., Nakane A., Yang Z. B., Minagawa T., Kobayashi H. Immunoregulatory cytokine release in rat spleen cell cultures after treatment with bleomycin and its analogues in vivo. Cancer Immunol Immunother. 1991;33(1):33–38. doi: 10.1007/BF01742525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Palù G., Valisena S., Ciarrocchi G., Gatto B., Palumbo M. Quinolone binding to DNA is mediated by magnesium ions. Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9671–9675. doi: 10.1073/pnas.89.20.9671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Riesbeck K., Andersson J., Gullberg M., Forsgren A. Fluorinated 4-quinolones induce hyperproduction of interleukin 2. Proc Natl Acad Sci U S A. 1989 Apr;86(8):2809–2813. doi: 10.1073/pnas.86.8.2809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Riesbeck K., Forsgren A. Increased interleukin 2 transcription in murine lymphocytes by ciprofloxacin. Immunopharmacology. 1994 Mar-Apr;27(2):155–164. doi: 10.1016/0162-3109(94)90050-7. [DOI] [PubMed] [Google Scholar]
  38. Riesbeck K., Gullberg M., Forsgren A. Evidence that the antibiotic ciprofloxacin counteracts cyclosporine-dependent suppression of cytokine production. Transplantation. 1994 Jan;57(2):267–272. doi: 10.1097/00007890-199401001-00020. [DOI] [PubMed] [Google Scholar]
  39. Riesbeck K., Sigvardsson M., Leanderson T., Forsgren A. Superinduction of cytokine gene transcription by ciprofloxacin. J Immunol. 1994 Jul 1;153(1):343–352. [PubMed] [Google Scholar]
  40. Rius C., Zorrilla A. R., Cabañas C., Mata F., Bernabeu C., Aller P. Differentiation of human promonocytic leukemia U-937 cells with DNA topoisomerase II inhibitors: induction of vimentin gene expression. Mol Pharmacol. 1991 Apr;39(4):442–448. [PubMed] [Google Scholar]
  41. Robinson M. J., Corbett A. H., Osheroff N. Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II. Biochemistry. 1993 Apr 13;32(14):3638–3643. doi: 10.1021/bi00065a016. [DOI] [PubMed] [Google Scholar]
  42. Robinson M. J., Martin B. A., Gootz T. D., McGuirk P. R., Moynihan M., Sutcliffe J. A., Osheroff N. Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage. J Biol Chem. 1991 Aug 5;266(22):14585–14592. [PubMed] [Google Scholar]
  43. Robinson M. J., Martin B. A., Gootz T. D., McGuirk P. R., Osheroff N. Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group. Antimicrob Agents Chemother. 1992 Apr;36(4):751–756. doi: 10.1128/aac.36.4.751. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Schaak J., Schedl P., Shenk T. Transcription of adenovirus and HeLa cell genes in the presence of drugs that inhibit topoisomerase I and II function. Nucleic Acids Res. 1990 Mar 25;18(6):1499–1508. doi: 10.1093/nar/18.6.1499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Schneider E., Hsiang Y. H., Liu L. F. DNA topoisomerases as anticancer drug targets. Adv Pharmacol. 1990;21:149–183. doi: 10.1016/s1054-3589(08)60342-7. [DOI] [PubMed] [Google Scholar]
  46. Shen L. L., Baranowski J., Fostel J., Montgomery D. A., Lartey P. A. DNA topoisomerases from pathogenic fungi: targets for the discovery of antifungal drugs. Antimicrob Agents Chemother. 1992 Dec;36(12):2778–2784. doi: 10.1128/aac.36.12.2778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Sugino A., Higgins N. P., Brown P. O., Peebles C. L., Cozzarelli N. R. Energy coupling in DNA gyrase and the mechanism of action of novobiocin. Proc Natl Acad Sci U S A. 1978 Oct;75(10):4838–4842. doi: 10.1073/pnas.75.10.4838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Wang J. C. DNA topoisomerases: why so many? J Biol Chem. 1991 Apr 15;266(11):6659–6662. [PubMed] [Google Scholar]
  49. Webb M. L., Maguire K. A., Jacob S. T. Novobiocin inhibits initiation of RNA polymerase II-directed transcription of the mouse metallothionein-I gene independent of its effect on DNA topoisomerase II. Nucleic Acids Res. 1987 Oct 26;15(20):8547–8560. doi: 10.1093/nar/15.20.8547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Xanthoudakis S., Miao G., Wang F., Pan Y. C., Curran T. Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme. EMBO J. 1992 Sep;11(9):3323–3335. doi: 10.1002/j.1460-2075.1992.tb05411.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Yamashita Y., Ashizawa T., Morimoto M., Hosomi J., Nakano H. Antitumor quinolones with mammalian topoisomerase II mediated DNA cleavage activity. Cancer Res. 1992 May 15;52(10):2818–2822. [PubMed] [Google Scholar]
  52. Zehavi-Willner T., Shalit I. The inhibitory effect of ciprofloxacin on proliferation of a murine bladder carcinoma cell line. J Antimicrob Chemother. 1992 Mar;29(3):323–328. doi: 10.1093/jac/29.3.323. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES